Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

588 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Limitations of current Parkinson's disease therapy.
Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL. Rascol O, et al. Ann Neurol. 2003;53 Suppl 3:S3-12; discussion S12-5. doi: 10.1002/ana.10513. Ann Neurol. 2003. PMID: 12666094 Review.
Does ageing influence deep brain stimulation outcomes in Parkinson's disease?
Ory-Magne F, Brefel-Courbon C, Simonetta-Moreau M, Fabre N, Lotterie JA, Chaynes P, Berry I, Lazorthes Y, Rascol O. Ory-Magne F, et al. Among authors: rascol o. Mov Disord. 2007 Jul 30;22(10):1457-1463. doi: 10.1002/mds.21547. Mov Disord. 2007. PMID: 17516457 Clinical Trial.
Dopamine agonists.
Rascol O, Slaoui T, Regragui W, Ory-Magne F, Brefel-Courbon C, Montastruc JL. Rascol O, et al. Handb Clin Neurol. 2007;84:73-92. doi: 10.1016/S0072-9752(07)84033-4. Handb Clin Neurol. 2007. PMID: 18808942 No abstract available.
Skin cancer and Parkinson's disease.
Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, Sampaio C. Ferreira JJ, et al. Among authors: rascol o. Mov Disord. 2010 Jan 30;25(2):139-48. doi: 10.1002/mds.22855. Mov Disord. 2010. PMID: 20063399 Free article. Review.
Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.
Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Sablonniere B, Azulay JP, Tison F, Rascol O, Vidailhet M, Destée A, Bloem BR, Bordet R, Devos D; Parkgait-II study group. Moreau C, et al. Among authors: rascol o. Lancet Neurol. 2012 Jul;11(7):589-96. doi: 10.1016/S1474-4422(12)70106-0. Epub 2012 Jun 1. Lancet Neurol. 2012. PMID: 22658702 Clinical Trial.
Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial.
Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O; NS-Park CIC Network. Ory-Magne F, et al. Among authors: rascol o. Neurology. 2014 Jan 28;82(4):300-7. doi: 10.1212/WNL.0000000000000050. Epub 2013 Dec 26. Neurology. 2014. PMID: 24371304 Clinical Trial.
588 results